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dynamic performances that we reported in
our study and that were also confirmed by
other authors.3 This is quite unusual be-
cause, as the authors also state in their
article, the in vitro effective orifice areas
usually tend to overestimate the in vivo
effective orifice areas. Furthermore, hemo-
dynamic performances reported by Gerosa
and coauthors do not reflect the in vitro
hemodynamic performances reported for
the CE Perimount standard valve by Mar-
quez, Hon, and Yoganathan,4 even though,
as we already stressed, the valve itself is
not changed.
In conclusion we agree with the authors
that in vivo hemodynamic behavior of a
valve might differ from our idealized as-
sumption. However, we do believe that in
the case of prostheses with a supra-annular
design, such as the CE Perimount Magna,
in vivo performances could be improved
owing to the improved annulus-prosthesis
interaction. In vitro tests, like those re-
ported in this study, are extremely useful in
evaluating opening mechanism as well as
descriptive parameters for each prosthesis.
However, a real comparison of hemody-
namic performances of two valves with
such a different design as the Mitroflow
and CE Perimount Magna can be made
only in a randomized study evaluating cu-
mulative mean postoperative effective ori-
fice areas for two groups.
Pasquale Totaro
Vincenzo Argano
Cardiac Surgery Division
Morriston Hospital
Swansea, United Kingdom
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Reply to the Editor:
We appreciate the comments of Drs Totaro
and Argano on our recent article reporting
in vitro performances of 5 different aortic
tissue valves designed for supra-annular
implantation.1 To our minds, Drs Totaro
and Argano raised more questions than
comments, and we will discuss them in this
reply.
Supra-annular concept. During aor-
tic valve surgery, one of the main end points
should logically be to relieve as much steno-
sis as possible by ensuring that the indexed
effective orifice area (EOA) after the opera-
tion is above 0.85 to 0.90 cm2/m2.2 Hence, it
seems logical to implant supra-annular valves
that are placed on top of the aortic annulus.3
The Medtronic Mosaic, Carpentier-Edwards
Magna, Sorin Soprano, SJM-Biocor-Epic-
Supra, and Mitroflow valves all belong to
this category of prostheses. The concept of
supra-annular design is exclusively related
to the placement of a specifically designed
prosthesis, whether mechanical or biologi-
cal, on the top of the aortic annulus. The
patient annulus-prosthesis stent interaction
may explain why different valves are more
easily implanted than others, such as the
Sorin Soprano4 and the Mitroflow valves,
which have a flat profile. However, it can-
not explain differential hydraulic perfor-
mances. Unfortunately, at present, the hy-
pothetical differential hydraulic behavior
between different prosthetic heart valves
has not yet been sufficiently and compre-
hensively revealed.
The mounting ring of the pulse
duplicator may have influenced the
results. We tested production quality bio-
prostheses including the sewing ring cuffs
secured in between the 2 O-rings of the
pulse duplicator holder. To allow a mean-
ingful comparison regardless industry-la-
beled valve size, we tested the supra-annu-
lar tissue valves with a tissue annulus
diameter that could be fit in a 21-mm pulse
duplicator ring. Owing to the supra-annular
configuration, the opposite ring to fix the
valve measured a size larger than the first
(23 mm), therefore mimicking patient an-
nulus-prosthesis interaction. The valves
and the holder were sealed before testing.
We agree with Drs Totaro and Argano that
the pulse duplicator holder has a flat pro-
file. Nevertheless, we selected a relatively
homogeneous group of valves by using
those with the largest tissue annulus diam-
eter that could be superimposed in a defi-
nite pulse duplicator ring, without forcing
the insertion, to avoid stent modification.
We are fully aware that the distortion of the
normal planar geometry of the pericardial
prosthesis, induced by fixation with a sec-
ond inadequate ring, may result in failure
of adequate central leaflet coaptation. This
was not the case in our study. Unfortu-
nately, Totaro and Argano failed to con-
structively and fully explain how the
mounting ring of the pulse duplicator may
influence the comparison of different tissue
valves analyzed under identical conditions.
Our in vitro hydrodynamic perfor-
mances do not reflect the in vivo re-
sults reported by Totaro and associ-
ates.5 The EOA, the most commonly used
parameter for prosthetic heart valve com-
parison, is usually calculated by dividing
the flow measured in the left ventricular
outflow tract by transvalvular velocity.
Meanwhile, whereas the EOA was initially
believed to be a flow-independent parame-
ter, Kadem and coauthors6 recently sug-
gested that it is actually a flow-related pa-
rameter. Therefore, the predominance of
unsteady effects at low flow rates may be
further considered in measuring prosthetic
EOA.6 Moreover, as recommended by the
American Society of Echocardiography,7
measurements should be made over 3 cy-
cles in sinus rhythm or over 6 cycles in
atrial fibrillation. It is further suggested that
regurgitant jets also be calculated. These
should be localized and then graded by a
combination of the diameter of the base of
the jet and the density and slope of the
aortic regurgitant signal. Additionally, fo-
cusing on prosthetic heart valve compari-
son, the in vivo values should ideally be
measured 1 year after the operation, be-
cause the latter may change during the first
postoperative year.2 Concerning the pres-
sure recovery phenomenon, it has been
shown that mild stenosis, such as in a pa-
tient with a prosthesis, and a small aortic
root may lead to confounding echocardio-
graphic results.8 Pibarot and Dumesnil2
also observed that the impact of a mis-
match may be overestimated in these pa-
tients; thus, under the same indexed EOA,
patients with a smaller aorta will have less
energy loss and less burden on their left
ventricle than those with a larger aorta.
To summarize, unfortunately, in vivo
studies are not only limited by echocardio-
graphic technical pitfalls, but also different
clinical setting may intervene, leading to
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misleading examinations, such as aortic
root dimension and compliance,9 systemic
arterial pressure,10,11 angiotensin-convert-
ing enzyme inhibitors assumption effect,12
heart rate effect,8 and surgeon-related con-
founding factors.4,13
A contemporaneous, prospective, non-
randomized study has been published by
Botzenhardt and associates3 and was refer-
enced by Drs Totaro and Argano in their
letter. Botzenhardt and coauthors,3 by com-
paring supra-annular tissue valves of differ-
ent types, concluded that the Carpentier-Ed-
wards Magna valve is “the gold standard” in
the panorama of supra-annular tissue valves.
Moderate and severe mismatches were ob-
served in 8.7% in the Magna group, 41.5% in
the Perimount group, 40% in the Mosaic
group, and 50% in the Soprano group.3 The
patients were comparable regarding preoper-
ative and operative data, including number of
patients, sex, age, body surface area, cardiac
rhythm, New York Heart Association func-
tional class, left ventricular mass index, valve
size, and concomitant procedures. Unfortu-
nately, in this nonrandomized study, the pa-
tients were not compared according to the
stroke volume, as previously advised by the
same authors14; moreover, the patients were
followed up within 10 days postoperatively
by transthoracic echocardiography, contrary
to the previous echocardiographic recom-
mendations.7 Finally, the study results are
based on 48 patients with a Perimount, 35
patients a Magna, 42 with a Mosaic, and only
16 with a Soprano valve, although the pa-
tients were more numerous than in Totaro
and associates’ study.5
In conclusion, unfortunately, both of
these in vivo studies on aortic tissue valves,
to a greater or lesser degree, miss the point.
Although the timing of the echocardio-
graphic analysis in the Totaro paper is one
area criticized by Dr Kon and is cited as a
limitation of the study,5 the authors pub-
lished the article with a title that makes it
seem like a lure for larks. Furthermore, the
data discussed in the Totaro article5 are not
the results of a “size by size analysis” be-
tween patients owing to the poor consis-
tency of the cohort. Additionally, none of
the papers previously discussed3,5 focused
on the diastolic phase of the cardiac cycle,
and everyone ignored prosthesis regurgita-
tion. In none of these studies was either the
pressure recovery phenomenon or the aor-
tic root dimension mentioned. Finally, be-
sides all the limitations related to the echo-
cardiographic measurements, in neither
article was the systemic pressure or the
effect of angiotensin-converting enzyme
inhibitors considered. Maybe all these con-
siderations explain why our in vitro results
did not respect in vivo hemodynamic pros-
thetic performance.
Hydrodynamic performances re-
ported by Gerosa and associates1 do
not reflect in vitro performances re-
ported by Marquez, Hon, and Yo-
ganathan.15 Some authors observed that
in vitro and in vivo measurements were
comparable, although the in vitro usually
overestimate in vivo values by 10% to
15%.16,17 We did not make that observa-
tion.1 That is one of the main future objec-
tives of our studies. Worldwide, it is com-
monly maintained that the actual size and
valve dimensions vary considerably from
the labeled manufacturers’ diameters and,
furthermore, the labeled size is unrelated to
any hemodynamically significant dimen-
sion.2,13 Our recent findings1 parallel those
of previous authors,18 since in all the mea-
sured valves there was evidence that the
actual size and valve dimensions vary con-
siderably from the labeled diameters. As a
matter of fact, a comparison between Mar-
quez, Hon, and Yoganathan15 and our data
is meaningless, because all test data pre-
sented in the former study were obtained at
the Edwards Lifesciences LLC Product
Evaluation Laboratory in Irvine (formerly a
division of Baxter Healthcare, Inc). Addi-
tionally, in the Marquez study15 the pros-
theses were mounted on a rubber aortic
root annulus, making their results not com-
parable with ours.1 The in vitro system that
we have used has a virtually rigid arrange-
ment section downstream from the aortic
valve, which represents perhaps the single
largest distortion from reality. Attaching a
small compliant device to the downstream
section could yield a significantly different
system performance, mimicking an in vivo
setting such as an aortic setting. However,
if we compared two heart valves in this
modified system, we would expect to ap-
preciate the same differences between the
two different valves. Therefore, the pulse
duplicator device is not really designed to
give an accurate representation of the true
anatomy; instead, it is a system that pro-
vides an extraordinary and unquestionable
bench test for comparison of different pros-
theses. Indeed, pericardial valve prostheses
tested in our study1 exhibited the smallest
transprosthetic mean and peak gradients and
the lowest stroke work loss in comparison
with porcine valves, such as previously ob-
served.19 However, we could not observe
significant hydrodynamic differences be-
tween the pericardial prostheses, although
at increasing cardiac outputs (7 L/min) the
Mitroflow valve performed significantly
better.
Conclusions. The fundamental point
is this: We are more interested in the he-
modynamic performance that a patient with
an aortic annulus of 20 mm can expect after
aortic valve replacement with a given pros-
thesis. This is a very good point raised by
Eichinger’s group.14
Unfortunately, in vivo studies compar-
ing different prostheses are difficult and,
although randomized and well conducted,
they are misleading. Several confounding
factors, previously discussed, are fre-
quently present, and they may confound
the data obtained by echocardiographic
studies. On the contrary, all these unfore-
seeable factors may be checked and added
or removed at will during in vitro testing.
For these reasons, we maintain that it is
hazardous to conclude that a prosthesis
model is the gold standard by interpreting
only clinical results.
In conclusion, the most striking finding
of an in vitro study is the ability to obtain a
unique hydrodynamic comparison of dif-
ferent models of supra-annular tissue
valves fitting a specified artificial aortic
annulus, regardless of the size indicated by
the manufacturer’s label.
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Papillary fibroelastoma of aortic
valve: Early diagnosis and surgical
management
To the Editor:
We read with great interest the article by
Vagefi and associates1 regarding their ex-
perience with papillary fibroelastoma of the
aortic valve. We had a similar experience
with 2 patients having very small papillary
fibroelastomas who were referred to us and
had their tumors excised urgently.
A 68-year-old woman presented to her
general practitioner with a 3-month history
of symptoms including one transient isch-
emic attack (TIA).2 The patient subsequently
underwent echocardiography, which demon-
strated a mobile mass attached by a thin stalk
to the aortic valve. A 15-mm long and 2 mm
in diameter tumor attached to the noncoro-
nary cusp of the aortic valve was resected
with standard cardiopulmonary bypass.
A 67-year-old man was referred with a
recent history of multiple TIAs. Various
investigations including carotid Doppler
and transthoracic echocardiogram were in-
conclusive. However transesophageal echo-
cardiography (TEE) revealed a 5  1-mm
pedunculated tumor attached to the aortic
valve. At the time of surgery, a small tumor
with a thin stalk was found attached to the
undersurface of the left coronary cusp
(Figure 1). Both patients had an uncom-
plicated recovery and were discharged
home on day 5.
Our patients were very similar to the
case reported by Vagefi and colleagues in
that both had an early diagnosis of the
tumor made by echocardiography on the
basis of neurologic symptoms. Both of our
patients had their tumors shaved off the
structurally normal aortic valve on an ur-
gent basis. At the conclusion of the proce-
dure, intraoperative TEE demonstrated a
competent aortic valve with no evidence of
residual tumor or aortic insufficiency.
It seems that an early diagnosis of these
tumors is being made with very small masses
detected with echocardiography. We empha-
size the importance of prompt excision of
these tumors owing to the risk of preopera-
tive thromboembolic phenomena.3
Pankaj Saxena, MCh, DNB
Igor E. Konstantinov, MD, PhD
Andrew Lee, MBBS
Mark A. J. Newman, FRACS
Department of Cardiothoracic Surgery
Sir Charles Gairdner Hospital
Nedlands, WA, Australia
Figure 1. Papillary fibroelastoma excised from aortic valve of patient 2.
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